Back to search
FDAFDA · Food and drugs·Recall number Z-0978-2024

BO-RF-32-USA RotaFlow Centrifugal Pump with SOFTLINE Coating, Product Code 701047553. For use with an extracorporeal cardiovascular or cardiopulmonary bypass circuit.

Published February 14, 2024 · Recall initiated: January 8, 2024

Summary

FDA records medical device Class II recall Z-0978-2024, published February 14, 2024 and initiated January 8, 2024. Recalling firm: Maquet Medical Systems USA; Status: Ongoing; Reported quantity: 1090 total; Lot: UDI-DI 4037691650326 Lots 3000283239 and 3000330438 ***Lots added 3/21/24*** 3000334430; 3000344495; 3000351245. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Ongoing — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Nonconformities at their seal could potentially compromise the sterile barrier for affected products. Breach of sterile barrier could expose patients to pathogenic agents, resulting in the following potential harms: inflammation, infection, or sepsis.

What to do

Voluntary: Firm initiated · Letter

Get an email when a new FDA recall like this is published

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Manufacturer
Maquet Medical Systems USA
Distributor
Worldwide - US Nationwide distribution to the states of CA, IL, MD, MO, NC, NY, OH, OR, PA, TX, UT, VA and the countries of Canada, Germany, Italy, Japan, and Netherlands.
Lot
UDI-DI 4037691650326 Lots 3000283239 and 3000330438 ***Lots added 3/21/24*** 3000334430; 3000344495; 3000351245
Risk classification
Class II
Area (FDA)
device
Country
United States

Related recalls

Questions about this recall

Was BO-RF-32-USA RotaFlow Centrifugal Pump with SOFTLINE Coating, Product Code 701047553. For use with an extracorporeal cardiovascular or cardiopulmonary bypass circuit. recalled?

Yes. FDA published recall Z-0978-2024 on February 14, 2024. Reported hazard: Nonconformities at their seal could potentially compromise the sterile barrier for affected products. Breach of sterile barrier could expose patients to pathogenic agents, resulting in the following potential harms: inflammation, infection, or sepsis.

What should I do if I have this product?

Voluntary: Firm initiated · Letter